REPLIMUNE GROUP, INC. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
REPLIMUNE GROUP, INC. (REPL) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent of -24.30% for the 12-month period ending 2025-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-06-29
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2025 was -24.30%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2024 was -21.40%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2023 was -23.60%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2022 was -31.10%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 12 month |
|---|---|
| 2025-03-31 | -24.30% 10-K · filed 2026-06-29 |
| 2024-03-31 | -21.40% 10-K · filed 2025-05-22 |
| 2023-03-31 | -23.60% 10-K · filed 2024-05-16 |
| 2022-03-31 | -31.10% 10-K · filed 2023-05-18 |
| 2021-03-31 | -25.90% 10-K · filed 2022-05-19 |
| 2020-03-31 | -16.00% 10-K · filed 2021-05-20 |
| 2019-03-31 | -15.50% 10-K · filed 2020-06-03 |
| 2018-03-31 | -14.00% 10-K · filed 2020-06-03 |
| 2017-03-31 | -19.20% 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |